All In Biotech

Drug Trial Radar · NCT06418178

Dose Optimization of MDMA-Assisted Therapy for PTSD

A Dose Optimization Study of MDMA-Assisted Therapy for PTSD in U.S. Veterans

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jun 3, 2025

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Bronx VA Medical CenterFederal agency
Sponsor type
Federal agency
First posted
May 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open label, within-subjects dose optimization trial will investigate the optimal number of MDMA-Assisted Therapy treatment cycles (i.e., one MDMA session and three integration sessions) in a sample of U.S. veterans with PTSD. Participants will complete from one to five cycles of MDMA-AT.

Conditions

  • Posttraumatic Stress Disorder

Interventions

  • MidomafetamineDrug

    One to five MDMA-assisted therapy sessions, each followed by three non-drug psychotherapy sessions (see behavioral intervention below)

  • PsychotherapyBehavioral

    Standardized psychotherapy performed by therapy team

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PTSD Checklist for DSM-5 (PCL-5)Time frame: From Baseline to Outcome Site Visit (up to ~27 weeks for participants who complete all five treatment cycles)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • James J. Peters VA Medical Center

    The Bronx, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.